Application of RIPK3 protein in improving immune safety and immunogenicity of newcastle disease live vaccine embryo
By inhibiting the activity of RIPK3 protein, using the RIPK3 inhibitor GSK840, the problem of insufficient toxicity and immune effect of the live Newcastle epidemic vaccine on chicken embryos was solved, significantly improved the hatching rate and survival rate, and enhanced the immune response of chicks, achieving Safer and efficient embryo immune protection.
Patent Information
- Application Number
- CN202411145056.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-22
AI Technical Summary
The existing live Newcastle epidemic vaccine has strong virulence on chicken embryos, resulting in a decrease in hatching rate and a high mortality rate of hatched chicks. It is difficult to pass intraembryonic immunization and cannot provide satisfactory early immune protection.
By inhibiting the activity of the key protein RIPK3 in cell necrotizing apoptosis, the use of RIPK3 protein inhibitor GSK840, significantly improves the hatching and survival rate of the live Newcastle Vaccine vaccine on chicken embryos, and enhances the HI antibody level of chicks, improving the safety of the vaccine and Immunogenicity.
It significantly improves the hatching and survival rate of the live Newcastle epidemic vaccine on chicken embryos, enhances the immune response of chicks, and provides safer and more efficient embryo immune protection.
Smart Images

Figure CN118987190A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of veterinary vaccines, and specifically relates to the application of RIPK3 protein in improving the embryonic immune safety and immunogenicity of Newcastle disease live vaccine. Background Art
[0002] Newcastle disease is a highly contagious, acute, and severe infectious disease caused by Newcastle disease virus (NDV). It can infect a variety of poultry and poses a huge threat to my country's poultry industry. Vaccination is one of the effective measures to prevent and control Newcastle disease. In large-scale farms, the mass delivery of vaccines is an important way to improve the efficiency of vaccination, save labor costs, and reduce costs and increase efficiency.
[0003] In the late stage of chicken embryonic development (about 18 embryonic ages), the immune system of the chicken embryo is basically fully developed and has normal immune response ability. The early immune system of the embryo can be activated by intra-ovo vaccination, providing early immune protection for the chicks and shortening the immune blank period. In-ovo immunization technology was proposed as early as the 1980s and gradually commercialized in the 1990s. At present, many countries in the world, including the United States, use this technology for early hatchery immunization of Marek's disease and infectious bursal disease. Compared with traditional immunization technology, intra-ovo immunization has the following advantages: 1) It can induce chicks to produce specific immunity earlier and fill the immune blank period; 2) The immune effect is uniform and reliable; 3) In-ovo vaccination of combined vaccines can reduce the frequency of immunization of chicks and avoid stress reactions and deaths during the immunization process; 4) Automated platform immunization can significantly increase the vaccination speed and greatly reduce the consumption of human resources. With the improvement of the intensive breeding level of my country's poultry industry, intra-ovo immunization has broad development prospects and is expected to play an important role in the prevention and control of poultry diseases.
[0004] However, there is no NDV-based Newcastle disease vaccine suitable for in-ovo immunization on the market. The La Sota strain is the most widely used live vaccine, which is mainly administered by nasal drops, eye drops, drinking water, spray, etc. However, La Sota has strong virulence to chicken embryos. Vaccination of 18-day-old chicken embryos causes a significant decrease in hatching rate and a high mortality rate of hatched chicks. Therefore, LaSota cannot be used directly for in-ovo immunization. In addition, the antibody response induced by the LaSota vaccine in 1-day-old newborn chicks is weak, making it difficult to provide satisfactory early immune protection. International Animal Health has launched a viral vector vaccine that uses turkey herpes virus (HVT) as a vector to express NDV fusion protein, which can be administered through in-ovo immunization. However, it should be pointed out that due to serious interference between HVTs, more than two HVT vaccines cannot be used simultaneously in the same farm; and HVT needs to be stored in liquid nitrogen. Therefore, it is urgent to develop a new Newcastle disease embryo vaccine. Therefore, improving the safety and immunogenicity of NDV attenuated live vaccines to embryos is the bottleneck that must be overcome first in the development of new Newcastle disease embryo vaccines and the promotion of clinical application of in-ovo immunization technology. Summary of the invention
[0005] In order to overcome the problem of poor toxicity and immune effect of NDV attenuated live vaccine on embryo immunity, the present invention provides the application of RIPK3 protein in improving the embryo immunity safety and immunogenicity of Newcastle disease live vaccine. The present invention selects the clinically widely used NDV attenuated strain La Sota, first evaluates the virulence of the virus to 18-day-old chicken embryos and hatched chicks; then screens the host cell death-related genes that change significantly after virus infection; further selects the key protein RIPK3 of cell necroptosis as the target, and evaluates the effect of RIPK3 inhibitor GSK840 on the virulence and immunogenicity of LaSota on chicken embryos and chicks. The present invention finds that the key protein RIPK3 of cell necroptosis has an important effect on the embryo toxicity of NDV attenuated vaccine, and inhibiting the activity of RIPK3 can significantly improve the hatching rate and survival rate of virus-inoculated chicken embryos, and significantly enhance the HI antibody level of chicks. The present invention provides a new application of RIPK3 protein in improving the embryo safety and immunogenicity of NDV attenuated live vaccine, and has a good application prospect in the development of safe and efficient Newcastle disease embryo vaccine.
[0006] The purpose of the present invention is achieved through the following technical solutions: The application of RIPK3 protein in improving the embryo immunity safety and immunogenicity of Newcastle disease live vaccine, wherein the sequence of the RIPK3 protein is a protein composed of the amino acid sequence shown in Genbank NO. XP_040536973.1.
[0007] Furthermore, the application includes: improving the hatching rate and survival rate of chicks after embryo immunization with Newcastle disease live vaccine by inhibiting the activity of RIPK3 protein.
[0008] Furthermore, the Newcastle disease live vaccine is the La Sota strain.
[0009] Furthermore, the sequences of the primers for detecting the expression level of the RIPK3 gene are shown in SEQ ID NOs. 27-28.
[0010] Furthermore, a RIPK3 protein inhibitor was used to inhibit the activity of RIPK3 protein.
[0011] Furthermore, the RIPK3 protein inhibitor is GSK840.
[0012] Furthermore, the RIPK3 protein inhibitor is used to inhibit the activation of the necroptosis execution protein MLKL in chicks after embryo immunization with Newcastle disease live vaccine.
[0013] Furthermore, the dosage of the RIPK3 protein inhibitor is 0.2-0.5 mg / embryo.
[0014] Furthermore, the sequences of the primers for detecting the viral load of the Newcastle disease virus are shown in SEQ ID NOs. 33-34.
[0015] The present invention also provides the use of RIPK3 protein in improving the embryo immunogenicity of Newcastle disease live vaccine, wherein the sequence of the RIPK3 protein is a protein composed of the amino acid sequence shown in Genbank NO. XP_040536973.1.
[0016] Furthermore, the application includes: improving the HI antibody level of chicks after embryo immunization with Newcastle disease live vaccine by inhibiting the activity of RIPK3 protein.
[0017] First, 18-day-old chicken embryos were inoculated with the attenuated live NDV vaccine La Sota at a dose of 10 4 EID 50 , determine the hatching rate of chicken embryos and the survival rate of chicks after virus infection.
[0018] Furthermore, the lungs, livers and duodenums of unhatched dead chicks and hatched chicks were collected, and the expression levels of cell death and inherent immunity-related genes in the tissues were detected using relative fluorescence quantitative PCR method, and the primers were shown in SEQ ID NO.1-32.
[0019] Furthermore, an absolute fluorescence quantitative PCR method was established to determine the level of viral replication in the lungs, livers, and duodenum of chicks. Using the La Sota NP (GenBank: OR826377.1) gene as a template, upstream and downstream primers and probes for absolute fluorescence quantitative analysis were designed, as shown in SEQ ID NO.33-35. The 5' end of the probe was a FAM fluorescent group, and the 3' end was an MGB fluorescent group. Using the 1-2383 nt gene of La Sota as a template, a pair of primers were designed, the sequences of which are shown in SEQ ID NO.36 and SEQ ID NO.37, and the 1-2383 nt gene fragment of La Sota was amplified. The sequence of the amplified fragment is shown in SEQ ID NO.38; the gene fragment was cloned into the pCE2TA / Blunt-Zero vector, and the successfully constructed plasmid was used as the standard plasmid for absolute fluorescence quantitative PCR.
[0020] Furthermore, absolute fluorescence quantitative PCR was used to detect the number of La Sota virus copies in the lung, liver, and duodenum. The number of copies of the standard was calculated, and the standard was diluted 10 times to draw a standard curve. The following system was configured in the qPCR tube: 2 × AceQ qPCR Probe Master Mix 10 ul, Primer 1 (10 µM) 0.4 ul, Primer 2 (10µM) 0.4 ul, TaqMan Probe (10 µM) 0.2 ul, cDNA 1 ul, ddH2O 7 ul. The reaction procedure was: pre-denaturation Reps: 1, 95℃ 5 min, cycle reaction Reps: 40, 95℃ 10 sec 60℃ 30 sec. The Ct value was substituted into the standard curve to calculate the copy number.
[0021] Furthermore, based on the analysis of the host response in virus-infected chicken embryos, necroptosis with a large range of changes was selected as the research target. First, the necroptosis response was blocked by inhibiting RIPK3 activity through drug treatment. The RIPK3 inhibitor GSK840 was inoculated into 18-day-old chicken embryos via intraembryo injection, with drug doses of 0.2, 0.5, and 1.0 mg / embryo, and the hatching rate of chicken embryos, chick survival rate, and body weight changes were recorded.
[0022] Furthermore, GSK840 and La Sota were inoculated simultaneously into 18-day-old chicken embryos at doses of 0.2 and 0.5 mg / embryo, and the hatching rate, chick mortality, body weight changes and clinical manifestations were recorded.
[0023] Furthermore, within 14 days after the chicks were hatched, the lungs of the dead chicks in each group were collected; after 14 days, the lungs of the surviving chickens in each group were collected.
[0024] Furthermore, the Western blot method was used to detect the expression levels of RIPK3 and MLKL proteins, and absolute fluorescence quantitative PCR was used to determine the viral load in the lungs.
[0025] Furthermore, serum from surviving chickens 14 days after virus inoculation was collected to determine HI antibody titers. Beneficial Effects
[0026] The virulence of the virus is closely related to the host cell death response it induces. Necrosis is one of the important types of cell death induced by viral infection. Cells undergoing necroptosis will rupture, release intracellular substances, stimulate inflammatory responses, and enhance the pathogenicity of the virus. The signal transduction process of necroptosis includes: receptor-interacting protein kinase 1 (RIPK1) interacts with RIPK3, the kinase activity of RIPK3 phosphorylates and activates its downstream mixed lineage kinase domain-like (MLKL) protein, and the activated MLKL oligomerizes to form a cell membrane perforation complex, leading to cell lysis. Inhibiting necroptosis induced by viral infection by targeting RIPK3 can significantly reduce the pathogenicity of diseases such as influenza, and is a new target for the development of antiviral drugs. Therefore, regulating necroptosis is a feasible way to regulate viral virulence.
[0027] The present invention provides a potential mechanism by which the NDV attenuated live vaccine La Sota causes death to chicken embryos, namely, host cell death response activated by virus infection may lead to the death of chicken embryos and the morbidity and mortality of hatched chicks, thereby overcoming the technical problem that the Newcastle disease live vaccine LaSota strain can only be inoculated by nasal drops, eye drops, drinking water, spraying and the like, and cannot be directly used for intra-embryo inoculation, thereby providing a new idea for further improving the safety of the NDV live vaccine.
[0028] The present invention provides a new application of RIPK3 protein in improving the safety and immunogenicity of NDV embryo vaccines, and provides a new target for solving the problems of embryo toxicity and immune efficacy of existing NDV live vaccines. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 The graphs show the expression levels of genes related to cell death and natural immunity in La Sota-inoculated chicken embryos; wherein Graph A shows the expression levels of genes related to immune response in the lungs of chicks; wherein Graph B shows the expression levels of genes related to immune response in the duodenum of chicks; wherein Graph C shows the expression levels of genes related to immune response in the livers of chicks.
[0030] Figure 2 This is the electrophoresis diagram of the gene fragment from nt 1 to 2383 of La Sota.
[0031] Figure 3 This is the electrophoresis diagram of NP standard plasmid restriction enzyme digestion.
[0032] Figure 4 This is the standard curve of LaSota viral load absolute fluorescence quantitative PCR.
[0033] Figure 5 Figure 2 shows the viral load of La Sota in the lung, liver, and duodenum of chicken embryos and hatching chicks.
[0034] Figure 6 This is a graph showing the weight changes of chicks treated with GSK840.
[0035] Figure 7 This is a graph showing the survival rate of chicks co-inoculated with GSK840 and LaSota.
[0036] Figure 8 This is a graph showing weight changes in chicks co-inoculated with GSK840 and LaSota.
[0037] Fig. 9 Figure 1 is an immunoblot of proteins related to lung necroptosis in chicks co-inoculated with GSK840 and LaSota; Figure A is the expression detection diagram of MLKL and p-MLKL proteins; Figure B is the gray value analysis diagram of MLKL and p-MLKL protein expression.
[0038] Fig.10 This is a graph showing the lung viral load of GSK840 in LaSota-infected chicks at 14 days of age.
[0039] Fig.11 This is a graph showing the HI antibody titer of chicks co-vaccinated with GSK840 and LaSota. DETAILED DESCRIPTION
[0040] Example 1 Evaluation of the toxicity of NDV La Sota strain to 18-day-old chicken embryos and chicks Twenty-eight 18-day-old SPF chicken embryos were randomly divided into two groups: 5 embryos in the PBS group and 23 embryos in the challenge group. 4 EID 50 The NDV attenuated live vaccine La Sota (provided by the Key Open Laboratory of Poultry Biological Products of the Ministry of Agriculture and Rural Affairs of Yangzhou University) was inoculated into 18-day-old chicken embryos via intraocular injection. The process is as follows: (1) The air cell side eggshell of the chicken embryo incubated for 18 days was disinfected with 70% ethanol; (2) A 1 mm hole was made at the top of the eggshell of the air cell; (3) A 23G needle was inserted into the chicken embryo about 1 inch, and 0.1 mL of diluted allantoic fluid was injected into the amniotic cavity; (5) After inoculation, the chicken embryo was sealed with glue or paraffin and placed in the incubator to prepare for transfer; (6) The embryos were irradiated 24 hours after inoculation, and dead embryos were discarded. After the virus attack, the number of hatchings, clinical symptoms and mortality of each group were recorded, and the hatching rate and survival rate were calculated.
[0041] As shown in Table 1, compared with chicken embryos not inoculated with the virus, the hatching rate of chicken embryos inoculated with the NDV attenuated strain La Sota decreased, and the hatched chicks showed typical respiratory and neurological symptoms of Newcastle disease, and all died within 8 days. The results show that La Sota has a strong virulence on 18-day-old chicken embryos and chicks.
[0042]
[0043] Example 2 Analysis of the innate immunity and cell death response induced by La Sota strain in chicks The lungs, livers, and duodenums of unhatched chicks and chicks that died after hatching were collected to measure the expression of genes related to innate immune response (IFN-α, TNF-α, etc.), apoptosis (caspase 3, caspase 8, etc.), necroptosis (RIPK3, MLKL, etc.), and pyroptosis (GSDME, IL-1β, etc.). The specific methods are as follows: 1. Tissue RNA Extraction (1) Grind the frozen tissue at low temperature until it becomes powder. Add 1 ml of VeZol Reagent for every 50-100 mg of tissue powder, vortex until there are no obvious lumps, and let it stand at room temperature for 5 min.
[0044] (2) Add 1 / 5 volume of chloroform to the above lysate. Shake vigorously for 15 seconds until the emulsion becomes turbid. Let stand at room temperature for 5 minutes. Centrifuge at 12,000 rpm (13,400×g) at 4℃ for 5 minutes.
[0045] (3) Carefully pipette the upper aqueous phase (about 500 μl) into a new RNase-free centrifuge tube.
[0046] (4) Add 0.5 times the volume of the aqueous phase of anhydrous ethanol and mix thoroughly.
[0047] (5) Transfer the mixed solution from the previous step to FastPure RNA Columns VI (RNA Columns have been placed in the collection tube), centrifuge at 12,000 rpm (13,400 × g) at 4°C for 30 sec, and discard the filtrate.
[0048] (6) Add 700 μl of Buffer RWA (with anhydrous ethanol) to FastPure RNA Columns VI, centrifuge at 12,000 rpm (13,400 × g) at 4°C for 30 sec, and discard the filtrate.
[0049] (7) Add 500 μl of Buffer RWB (with anhydrous ethanol) to FastPure RNA Columns VI, centrifuge at 12,000 rpm (13,400 × g) at 4°C for 30 sec, and discard the filtrate. Repeat this step.
[0050] (8) Place FastPure RNA Columns VI back into the collection tube and centrifuge at 12,000 rpm (13,400 × g) at 4°C for 2 min to prevent contamination by ethanol.
[0051] (9) Carefully transfer the adsorption column to a new RNase-free Collection Tubes 1.5 ml centrifuge tube, add 50 μl of RNase-free ddH2O (preheated to 65°C) in the center of the adsorption column, let it stand at room temperature for 5 min, centrifuge at 12,000 rpm (13,400 × g) at 4°C for 1 min to elute the RNA, and measure the concentration.
[0052] 2. Reverse Transcription (1) Prepare the following mixture in an RNase-free centrifuge tube: template RNA (add 500 ng), 4×gDNAwiper Mix 4 ul, and RNase-free ddH2O to 16 µl. Mix by gently pipetting and incubate at 42°C for 2 min.
[0053] (2) Add 4 ul of 5×HiScript II qRT SuperMix II directly to the reaction tube in the previous step. Mix by gently pipetting. Incubate at 50℃ for 15 min, then at 85℃ for 5 sec.
[0054] 3. Relative fluorescence quantitative PCR According to the sequence information of the gene to be tested, the fluorescent quantitative PCR primers were designed (see Table 2). The qPCR reaction system was: 2 × ChamQ SYBR Color qPCR Master Mix 10 μl, upstream primer, downstream primer 1 μl each, cDNA 2 μl, ddH2O 7 μl. The reaction procedure was: 95℃ pre-denaturation for 3 min, 95℃ 10 s, 60℃ 30 s, 40 cycles, and finally melting curve collection. The ct value collected by the instrument was analyzed using 2 -ΔΔct Methods The relative expression levels of genes were calculated.
[0055] Table 2 Primer sequences used for relative fluorescence quantitative PCR
[0056] like Figure 1 As shown, La Sota infection can induce significant upregulation of genes related to innate immunity and cell death in chicken tissues. The genes with higher upregulation in the lung and liver include RIPK3, IL-8, and MLKL; in the duodenum, the expression of IL-1β is significantly increased. The results show that La Sota virus can stimulate cell death response and innate immunity in chicks, among which the induction of necroptosis is more significant.
[0057] Example 3 Establishment of an absolute fluorescence quantitative PCR method for determining viral load A pair of primers and probes were designed according to the NP gene sequence of the La Sota strain (the upstream primer sequence is shown in SEQ ID NO.33; the downstream primer sequence is shown in SEQ ID NO.34; the probe sequence is shown in SEQ ID NO.35). Then, a plasmid standard containing the LaSota NP gene was constructed. A pair of primers was designed (the upstream primer sequence is shown in SEQ ID NO.36; the downstream primer sequence is shown in SEQ ID NO.37), and the gene fragment of La Sota 1-2383 nt was amplified by PCR (the amplified gene sequence is shown in SEQ ID NO.38). The PCR reaction system was: La Sota cDNA 2 μL, upstream primer 1 μL, downstream primer 1 μL, 2 × PhantaMaster Mix 12.5 μL. The reaction procedure was: 95℃ pre-denaturation for 3 min, 95℃ denaturation for 15 s, 60℃ annealing for 15 s, 72℃ extension for 2 min, 35 cycles, and finally 72℃ extension for 5 min. After verification by first-generation sequencing, the fragment was ligated into the pCE2 TA / Blunt-Zero vector. Figure 2 As shown in FIG. 1 , the gene fragment of NDV La Sota nt 1-2383 was amplified. Figure 3 As shown, the gene fragment of La Sota nt 1-2383 was successfully cloned into the pCE2 TA / Blunt-Zero vector. After the sequence was confirmed to be correct by first-generation sequencing, the construction of the standard plasmid was completed.
[0058] The standard plasmid was diluted 10-fold, and 6 dilutions of the standard were selected for drawing the standard curve. The following mixed solution was prepared in a qPCR tube: 2 × AceQ qPCR Probe Master Mix 10 ul, Primer1 (10 µM) 0.4 ul, Primer2 (10 µM) 0.4 ul, TaqMan Probe (10 µM) 0.2 ul, DNA 1 ul, ddH2O 7 ul. The reaction program was: pre-denaturation Reps: 1, 95℃ 5 min, cycle reaction Reps: 40, 95℃ 10 sec 60℃ 30 sec. The standard curve was obtained, see Figure 4 .
[0059]
[0060] Example 4 La Sota tissue viral load determination In order to explore the relationship between the viral load of La Sota and the expression of host response-related genes, the absolute fluorescence quantitative PCR established in Example 3 was used to detect the viral load of the lung, duodenum and liver. The cDNA of each organ obtained in Example 2 was used as a template. First, prepare the reaction system, 2 × AceQ qPCR Probe Master Mix 10 ul, Primer1 (10 µM) 0.4 ul, Primer2 (10 µM) 0.4 ul, TaqMan Probe (10 µM) 0.2 ul, cDNA 1 ul, ddH2O 7 ul. Then, set the reaction program as: pre-denaturation Reps: 1, 95°C 5 min, cycle reaction Reps: 40, 95°C 10 sec 60°C 30 sec. According to the obtained ct value, substitute it into the standard curve to obtain the copy number of La Sota in each tissue.
[0061] like Figure 5 As shown in the figure, the viral load of LaSota in the lung and liver of hatched chicks was significantly higher than that in unhatched chicks, and the viral load in the duodenum was significantly higher than that in unhatched chicks. The tissue viral load and host response-related gene expression trends of hatched and unhatched chicks were opposite, indicating that cell death and innate immune response may play an antiviral role.
[0062] Example 5 Effect of the necroptosis inhibitor GSK840 on the toxicity of LaSota strain to chicken embryos and chicks In order to clarify the effect of necroptosis on the virulence of LaSota strain on chicken embryos and chicks, chicken embryos were treated with GSK840, an inhibitor of RIPK3 activation, a key protein in the necroptosis signaling pathway, and then inoculated with the virus to observe the hatching conditions and survival rate of the chickens.
[0063] 1. Safety evaluation of GSK840 in 18-day-old chicken embryos First, the toxicity of the inhibitor GSK840 to chicken embryos was evaluated. Fifty 18-day-old chicken embryos were divided into 6 groups: PBS control group, 2% DMSO group, 5% DMSO group, and 10% DMSO group, with 5 embryos in each group; 0.2 mg GSK840 group, 0.5 mg GSK840 group, and 1.0 mgGSK840 group, with 10 embryos in each group. The drug was injected into the chicken embryos using the intraembryo inoculation technique. The specific method is shown in Example 1. The dosage for each embryo was 0.6 ml. The number of hatches was recorded, and the hatching rate was calculated. After hatching, the weight of the chickens was weighed and recorded every day. The weight gain data within 10 days was plotted after observation until the 10th day. As shown in Table 3, higher concentrations of DMSO can reduce the hatching rate of chicken embryos and affect the weight gain of chickens. From Figure 6 It can be seen that the weight gain of the 0.5 mg GSK840 group within 10 days was significantly higher than that of the 10% DMSO group and the 0.2 mg GSK840 group. The results show that the safe dose of GSK840 for 18-day-old chicken embryos is 0.2 mg and 0.5 mg / embryo. The above two doses were selected for the next step of research.
[0064]
[0065] 2. Effect of GSK840 on the toxicity of La Sota in 18-day-old chicken embryos 45 18-day-old chicken embryos were divided into 6 groups: PBS control group, LaSota+2% DMSO group, LaSota+5% DMSO group, 5 embryos in each group; LaSota group, LaSota+0.2 mg GSK840 group, LaSota+0.5 mg GSK840 group, 10 embryos in each group. Chicken embryos were treated with GSK840 and inoculated with 10 4 EID 50 La Sota virus, see Example 1 for specific methods. Record the number of chicken embryos hatched, calculate the hatching rate, weigh and record the body weight every day, observe until 14 days, and draw a weight growth chart and survival curve ( Figure 7). As shown in Table 4, the hatching rate of the uninfected control group was 100%, and the survival rate within 14 days was 80%; the hatching rate of chicken embryos inoculated with LaSota, LaSota+2%DMSO, and LaSota+5% DMSO was higher, but the survival rate within 14 days was only 30-40%, and the chicks showed obvious clinical symptoms; after treatment with 0.2 mg GSK840, the hatching rate and survival rate of LaSota-inoculated chicken embryos did not change significantly; after treatment with 0.5 mg GSK840, the hatching rate of virus-infected chicken embryos was 90%, the survival rate within 14 days was 90%, and the chicks showed no obvious clinical symptoms. Weight monitoring of surviving chickens showed ( Figure 8 ), compared with the negative control group, La Sota virus infection reduced the weight gain of chicks; compared with La Sota-infected chickens, 0.2 mg and 0.5 mg GSK840 treatment had no significant effect on the weight gain of virus-infected chicks. The results showed that GSK840, an inhibitor of necroptosis key point protein RIPK3, can significantly reduce the virulence of La Sota to 18-day-old chicken embryos and chicks.
[0066]
[0067] Example 5 Effects of GSK840 on necroptosis and viral replication in LaSota infected chicks 1. Effect of GSK840 on necroptosis in LaSota infected chicks The protein expression levels of RIPK3 and MLKL in the necroptosis pathway were detected by immunoblotting. The brief process is as follows: grind the lung tissue, and then lyse it with RIPA lysis buffer containing protease inhibitors and super nuclease at 4°C for 30 minutes; centrifuge at 12000 rpm for 10 min, collect the supernatant; add loading buffer, boil the sample at 100°C for 10 minutes; perform SDS-PAGE electrophoresis to separate the protein; transfer to PVFD membrane; block with TBST containing 5% skim milk at room temperature for 1-2 h; incubate with rabbit anti-MLKL antibody, rabbit anti-p-MLKL antibody, mouse anti-Vinculin antibody at 4°C overnight; add horseradish peroxidase (HRP)-labeled anti-mouse or anti-rabbit antibody as the secondary antibody; add chemiluminescent detection reagent for color development, and take pictures. Fig. 9 As shown, 0.5 mgGSK840 treatment could inhibit the activation of MLKL, the executioner protein of necroptosis, by LaSota in chicks.
[0068] 2. Effect of GSK840 on LaSota replication in chicks When the chicks were 14 days old, the lungs of the La Sota+5% DMSO group and the La Sota+0.5 mg GSK840 group were collected and the tissue viral load was determined by absolute fluorescence quantitative PCR.
[0069] like Fig.10 As shown, the lung viral load was low in the La Sota+5% DMSO group and the La Sota+0.5 mg GSK840 group, and there was no significant difference in the viral copy number between the two groups.
[0070] Example 6 Effect of GSK840 on Antibody Response of LaSota Infected Chickens The antibody levels of chicks inoculated with GSK840 and La Sota were measured. 14 days after virus inoculation, only 3 chickens survived in the La Sota infection group, while 9 survived in the GSK840 treatment group. The serum of the chickens was collected and the hemagglutination inhibition (HI) antibodies were measured. The specific process is as follows: (1) La Sota hemagglutination titer determination and preparation of 4 units of antigen ① Add PBS to a 96-well microplate, 25 μL per well; ② Add La Sota allantoic fluid to the first row, 25 μL per well, and mix well by pipetting; ③ Pipette 25 μL of virus solution from row 1 to row 2, pipette and mix, then pipette 25 μL to row 3, repeat the same operation, dilute to row 11, and discard the virus solution; ④ Add PBS, 25 μL per well; ⑤ Add 1% chicken red blood cell suspension, 25 μL per well, gently shake to mix, and incubate at room temperature for 40 min; ⑥ The agglutination of each well is compared with the blank well in row 12, and the highest dilution of the virus that completely agglutinates red blood cells is determined as the hemagglutination titer of the virus; ⑦ Dilute the virus to a HA titer of 2 log2, i.e. 4 units of antigen, based on the measured hemagglutination titer; (2) HI antibody assay: ① Add PBS to a 96-well microplate, 25 μL per well; ② Add the serum to be tested to the first row, 25 μL per well, and mix well by pipetting; ③ Pipette 25 μL of serum from the first row to the second row, pipette and mix, then pipette 25 μL to the third row, repeat the same operation, dilute to the tenth row, and discard; ④ Add 4 units of prepared antigen to row 11, 25 μL per well, gently shake to mix, and incubate at room temperature for 30 minutes; ⑤ Add 1% chicken red blood cell suspension, 25 μL per well, gently shake to mix, and incubate at room temperature for 40 min; ⑥ The highest serum dilution that can completely inhibit hemagglutination is determined as the serum HI titer.
[0071] like Fig.11 As shown, 14 days after virus inoculation, the average HI titer of La Sota-inoculated chickens was 6 log2, and the average HI titer of GSK840 and La Sota-inoculated chickens was 7.6 log2, which was significantly higher than that of the La Sota-inoculated group. The results show that GSK840 treatment can significantly increase the HI antibody level induced by La Sota in-embryo immunization.
[0072] Sequence Listing SEQ ID NO.33 (upstream primer sequence for La Sota absolute fluorescence PCR quantification) 5′AGTCCGCATCTTTTTGGTTAGC3′; SEQ ID NO.34 (downstream primer sequence for La Sota absolute fluorescence PCR quantification) 5′GGTACCACCTGCCGTGTTG3′; SEQ ID NO.35 (probe primer sequence for La Sota absolute fluorescence PCR quantification) 5'FAM AGCTCAAGAGAGGCC MGB3'; SEQ ID NO.36 (upstream primer sequence for amplifying the 1st-2383 nt gene fragment of La Sota) 5′ACCAAACAGAGAATCCGTGAG3′; SEQ ID NO.37 (downstream primer sequence for amplifying the 1st-2383 nt gene fragment of La Sota) 5′AGTCAGGAAAGACCGCAGAA3′; SEQ ID NO.38 (La Sota 1-2383 nt gene sequence)
Claims
1. Application of RIPK3 protein in improving the safety of embryo immunity of Newcastle disease live vaccine, characterized in that: The sequence of the RIPK3 protein is a protein composed of the amino acid sequence shown in Genbank NO. XP_040536973.
1.
2. The use according to claim 1, characterized in that: The application includes: improving the hatching rate and survival rate of chicks after embryo immunization with Newcastle disease live vaccine by inhibiting the activity of RIPK3 protein.
3. The use according to claim 1, characterized in that: The Newcastle disease live vaccine is the La Sota strain.
4. The use according to claim 2, characterized in that: The sequences of the primers for detecting the expression level of the RIPK3 gene are shown in SEQ ID NOs. 27-28.
5. The use according to claim 2, characterized in that: RIPK3 protein inhibitors were used to inhibit the activity of RIPK3 protein.
6. The use according to claim 5, characterized in that: The RIPK3 protein inhibitor is GSK840.
7. The use according to claim 5, characterized in that: The RIPK3 protein inhibitor is used to increase the HI antibody level of chicks after embryo immunization with Newcastle disease live vaccine.
8. The use according to claim 5, characterized in that: The RIPK3 protein inhibitor is used to inhibit the activation of the necroptosis execution protein MLKL in chicks after embryo immunization with Newcastle disease live vaccine.
9. Use of RIPK3 protein in improving embryonic immunogenicity of Newcastle disease live vaccine, characterized in that: The sequence of the RIPK3 protein is a protein composed of the amino acid sequence shown in Genbank NO. XP_040536973.
1.
10. The use according to claim 9, characterized in that: The application includes: improving the HI antibody level of chicks after embryo immunization with Newcastle disease live vaccine by inhibiting the activity of RIPK3 protein.
